Recombinant Human OX-2 membrane glycoprotein (CD200)

What is the basic structure of human CD200 protein?

CD200 (also known as OX-2) is a type-1 cell membrane glycoprotein belonging to the immunoglobulin superfamily. The CD200 gene is located on chromosome 3q13.2 and spans approximately 29,744 base pairs . The protein exists in three transcript variants:

• Variant 1: 2,226 bp long, containing 7 exons, encoding the 269 amino acid isoform a

• Variant 2: 2,301 bp long, containing 7 exons, encoding the 294 amino acid isoform b

• Variant 3: 2,085 bp long, missing an exon, encoding the 153 amino acid isoform c

When expressed recombinantly, human CD200 typically covers amino acids 31-232 and migrates as a 35-45 kDa protein due to glycosylation when analyzed by SDS-PAGE .

What is the cellular distribution pattern of CD200 in normal human tissues?

CD200 shows a distinctive distribution pattern across both lymphoid and non-lymphoid tissues:

Lymphoid tissues and cells:

• Approximately 20% of peripheral blood mononuclear cells (PBMCs)

• All CD19+ B cells express CD200

• Approximately 20% of CD3+ T cells express CD200

• 60% of activated T cells (CD25+CD3+) show elevated CD200 expression

• Almost all thymocytes express CD200, with higher expression on single-positive lineage-committed thymocytes

• In secondary lymphoid organs (tonsil, spleen), expression is primarily restricted to follicles

Non-lymphoid tissues:

• Vascular endothelium (particularly high endothelial venules)

• Syncytiotrophoblast membranes (placenta)

• Glomeruli of the kidney

• Neuronal cells

This distribution pattern suggests CD200 marks cell types that share a common need to regulate myeloid cellular biology .

What are the primary functional roles of CD200?

CD200 serves several key immunoregulatory functions:

• Immune tolerance maintenance: The CD200/CD200R axis plays a pivotal role in maintaining immune tolerance and protecting healthy tissues from unnecessary immune damage .

• Immunosuppression: Interaction of CD200 with its receptor(s) leads to attenuation of various immune responses, resulting in prolonged survival of transplanted allografts and, in some instances, decreased resistance to tumor growth .

• T-cell modulation: CD200 costimulates T-cell proliferation while paradoxically suppressing the adaptive immune response by inhibiting effector and memory T cell anti-tumor activity .

• Myeloid cell regulation: CD200 regulates myeloid cell activity in various tissues, which may be particularly important in maintaining immune privilege in locations such as the placenta .

• Disease modulation: CD200 plays important roles in regulating autoimmune diseases, allergy, infection, and bone homeostasis .

What are the recommended methods for detecting CD200 expression in clinical samples?

Several validated methods exist for detecting CD200 expression, with flow cytometry being the most widely utilized:

Flow cytometry methodology:

• Use antibodies like OX104 mAb that recognize native human CD200

• Analyze both percentage of CD200+ cells (with ≥30% often used as cutoff) and mean fluorescence intensity (MFI)

• For improved specificity, calculate relative fluorescence intensity (RFI) as the ratio of CD200 MFI on target cells to CD200 MFI on control cells

• Incorporate multicolor staining with other lineage markers (CD19, CD3, CD5, CD23) for comprehensive phenotyping

Immunohistochemistry approach:

• Particularly useful for tissue sections and bone marrow aspirates

• Look for membranous CD200 staining pattern

• Include appropriate positive and negative controls

For quantitative analysis, researchers report that geometric mean fluorescence intensity for CD200 in clinical samples (e.g., multiple myeloma) can vary by up to 32-fold between patients, highlighting the importance of standardized measurement approaches .

How can recombinant CD200 be optimally produced for research applications?

For producing high-quality recombinant human CD200:

• Expression system selection: HEK293 cells are recommended for mammalian expression to ensure proper glycosylation and folding. This system typically yields protein with >98% purity .

• Construct design considerations:

  • Include amino acids 31-232 for functional studies

  • Add appropriate tags for purification (while minimizing interference with function)

  • Consider codon optimization for the expression system used

• Quality control metrics:

  • SDS-PAGE analysis (expect migration at 35-45 kDa due to glycosylation)

  • Endotoxin testing (<1 EU/μg is suitable for functional studies)

  • Functional validation through binding assays with CD200R

• Storage and handling:

  • Aliquot to avoid freeze-thaw cycles

  • Store at -80°C for long-term stability

  • Handle with caution as this is an active protein that may elicit biological responses in vivo

What experimental designs are most appropriate for studying CD200-CD200R interactions?

When designing experiments to investigate CD200-CD200R interactions, consider:

In vitro binding assays:

• Surface plasmon resonance (SPR) to determine binding kinetics

• ELISA-based binding assays for high-throughput screening

• Cell-based reporter assays to assess functional outcomes of binding

Cell-based functional studies:

• Co-culture systems with CD200+ and CD200R+ cells

• Cytokine production assays (measure TNF-α, IL-2, and IFN-γ)

• T cell proliferation assays (using CFSE dilution or Ki67 expression)

• Cytotoxicity assays (particularly relevant for cancer immunotherapy studies)

Knockout/knockdown approaches:

• CD200 or CD200R knockout models

• siRNA or shRNA-mediated knockdown

• CRISPR-Cas9 gene editing

• Dominant-negative constructs

Quasi-experimental designs:
For clinical studies where randomization is not feasible, consider nonequivalent control group designs with matched subjects based on relevant characteristics .

How reliable is CD200 as a diagnostic marker for chronic lymphocytic leukemia (CLL)?

CD200 demonstrates excellent sensitivity but limited specificity for CLL diagnosis:

Diagnostic performance metrics:

• Sensitivity: 100% (all CLL patients express CD200)

• Specificity: Only 35.9% (many non-CLL B-cell malignancies also express CD200)

• Accuracy: Similar to other Matutes score markers (79.2%–86.7%), except surface immunoglobulin (SmIg) at 59.1%

Improved diagnostic algorithm:
Adding CD200 to the traditional Matutes score significantly improves diagnostic accuracy:

This modified system correctly identified 91.4% of CLL cases (including 56.3% of atypical CLL) and 94.9% of non-CLL cases .

Implementation recommendations:
Rather than using CD200 as a standalone marker, incorporate it into scoring systems such as:

• Matutes score + CD200

• CLLflow score (combining CD200, CD23/CD5, CD79b, FMC7)

• Simplified score system (CD5, CD23, CD200, SmIg)

How do researchers resolve conflicting data regarding CD200 expression and prognosis in leukemia?

Conflicting results regarding the prognostic significance of CD200 in CLL highlight important methodological considerations:

Sources of conflicting data:

Resolution approaches:

• Standardized measurement techniques:

  • Use RFI (ratio of CD200 MFI on CD19+ vs. CD19- cells) for more consistent results

  • Establish clear cutoff values based on large validation cohorts

• Multivariate analysis:

  • Include established prognostic factors (del11q, del13q14) in analyses

  • Control for confounding variables

• Stratified analysis:

  • Analyze prognostic impact separately in genetically defined subgroups

  • One study found lower CD200 RFI values associated with del11q, while higher values associated with del13q14

• Meta-analysis:

  • Combine data from multiple studies with careful attention to methodology differences

  • Weight studies based on methodological quality

The evolving consensus suggests CD200 expression may have context-dependent prognostic significance that varies with genetic background and treatment history .

What is the significance of CD200 expression in multiple myeloma and its impact on immunotherapy?

CD200 expression in multiple myeloma has emerged as a critical factor affecting immunotherapy response:

Expression patterns:

• 100% (15/15) of patient biopsies, including both newly diagnosed and relapsed/refractory cases, were CD200+ by flow cytometry

• 75% (6/8) of bone marrow aspirates from newly diagnosed MM cases showed membranous CD200 staining by immunohistochemistry

• Geometric mean fluorescence intensity varies 32-fold between patients (range: 203-6445)

Impact on CAR T-cell therapy:
CD200 expression on myeloma cells significantly impairs CAR T-cell function:

• Even low CD200 expression moderately suppresses CAR T-cell cytotoxicity

• Higher expression levels reduce antigen-specific cytokine production and proliferation

• These effects occur regardless of CAR target antigen (BCMA, TnMUC1) or costimulatory domain used

Experimental evidence:
In controlled experiments comparing CAR T-cell response to CD200+ vs. CD200- targets:

• BCMA CAR T cells exposed to CD200+ targets demonstrated only 10 unique polyfunctional subpopulations vs. 17 when exposed to CD200- targets

• CD200+ targets significantly impaired CAR T-cell expansion, Ki67 expression, and granzyme B production

Engineering solutions:
Several strategies have been developed to overcome CD200-mediated immunosuppression:

• CD200R knockout (CD200RKO) - showed mixed results with reduced cytotoxicity

• CD200R dominant negative (CD200RDN) - showed positive trends in vivo

• CD200R-CD28 switch receptor - most promising approach, enabling cells to proliferate more robustly with greater effector function

What molecular mechanisms underlie CD200-mediated immunosuppression?

CD200 exerts immunosuppressive effects through multiple signaling pathways:

Receptor engagement and downstream signaling:

• CD200 binding to CD200R initiates recruitment of the Dok2 adaptor protein

• Dok2 interacts with the SH2 domain on RasGAP to form a Dok2/RasGAP complex

• This complex inhibits Ras activation and disrupts signaling through the Ras/MAPK pathway

• Simultaneously, STAT3 signaling is suppressed

Cellular consequences:

• Myeloid cells: Reduced production of pro-inflammatory cytokines including TNF-α

• T cells: Decreased levels of CD4+ and CD8+ memory T cells

• Cytokine profile: Reduced production of Th1 cytokines (TNF-α, IL-2, IFN-γ)

This signaling cascade explains the observed immunosuppressive effects in multiple disease contexts, including cancer and autoimmune conditions .

How do researchers reconcile conflicting data regarding CD200's role as both T-cell costimulator and immune checkpoint?

CD200 exhibits an apparent paradox in T-cell biology:

Conflicting observations:

• CD200 is reported to costimulate T-cell proliferation

• CD200-CD200R interaction suppresses adaptive immune responses by inhibiting T-cell anti-tumor activity

• CD200 is upregulated on activated T cells (60% of CD25+CD3+ cells)

Proposed reconciliation mechanisms:

• Context-dependent signaling:

  • CD200R ectodomain may have an unappreciated role in T-cell metabolism

  • The CD200-CD200R interaction might affect immunological synapse dynamics

  • CD200R-mediated signaling can support T-cell activity in specific contexts

• Differential receptor engagement:

  • CD200 may interact with multiple receptors beyond CD200R1

  • Recent research shows that type 1 interferons can reprogram CD200R signaling toward increased IFN-γ production in response to TLR7/8 agonists

• Expression level thresholds:

  • Low levels of CD200-CD200R engagement may provide costimulation

  • High levels may trigger inhibitory pathways

• Alternative ligands hypothesis:

  • Uncharacterized low-affinity ligands may represent natural ligands for alternate CD200Rs

  • Reported interactions of CD200 with alternate CD200Rs may be non-physiological effects

Further research using precise receptor blocking and knockout models is needed to fully resolve this apparent contradiction.

What are the current controversies regarding CD200 as a ligand for different CD200R isoforms?

Significant controversies exist regarding CD200's role as a ligand for all reported CD200Rs:

Current conflicting viewpoints:

• Some studies support CD200 as a physiological ligand for both CD200R1 and alternate CD200Rs

• Other research suggests CD200 only physiologically interacts with CD200R1, with alternate CD200R interactions being non-physiological

Evidence supporting restricted binding:

• As-yet uncharacterized low-affinity ligands may represent the natural ligands for alternate CD200Rs

• Reported interactions of CD200 with alternate CD200Rs may represent pharmacological rather than physiological effects

Methodological challenges contributing to controversy:

• Differences in binding assay sensitivities

• Variations in recombinant protein preparations

• Lack of standardized functional readouts for receptor activation

• Limited structural data on CD200-CD200R interactions

Research approaches to resolve controversies:

• Comprehensive binding studies with purified proteins

• Crystallography to determine binding interfaces

• Competitive binding assays with potential alternate ligands

• Cell-specific knockout models for each receptor isoform

• Domain swapping experiments to identify critical binding regions

Understanding these interactions is crucial for developing targeted therapies that modulate specific aspects of CD200 biology .

How can researchers optimize CD200-targeted therapeutic strategies in cancer immunotherapy?

Emerging research suggests several approaches for CD200-targeted cancer immunotherapy:

Therapeutic strategies:

• Antibody-based approaches:

  • Anti-CD200 neutralizing antibodies

  • Anti-CD200R agonistic antibodies to reprogram signaling

  • Bispecific antibodies linking CD200+ tumor cells to immune effectors

• Cell therapy engineering:

  • CD200R-CD28 switch receptors that convert inhibitory signals to costimulatory ones

  • CD200R dominant negative constructs

  • CRISPR-based CD200R knockout in therapeutic cells

• Small molecule modulators:

  • Compounds targeting the CD200-CD200R interaction

  • Inhibitors of downstream signaling components (Dok2, RasGAP)

Disease-specific considerations:

For chronic lymphocytic leukemia:

• High CD200 expression correlates with specific genetic alterations

• Lower CD200 RFI values associate with del11q

• Higher CD200 RFI values associate with del13q14

For multiple myeloma:

• 100% of patient samples express CD200 at levels sufficient to inhibit CAR T cells

• CD200R-CD28 switch receptors show the most promise for overcoming inhibition

• These modified CAR T cells displayed 26 unique polyfunctional subpopulations vs. only 10 for standard CAR T cells when exposed to CD200+ targets

Implementation considerations:

• Careful patient stratification based on CD200 expression levels

• Combination approaches targeting multiple immune checkpoints

• Biomarker development to predict response to CD200-targeted therapy

These strategies highlight the potential of targeting the CD200-CD200R axis as a novel approach to enhance cancer immunotherapy efficacy, particularly for hematological malignancies .

What new experimental approaches should researchers consider for investigating CD200 biology?

Researchers exploring CD200 biology should consider these cutting-edge approaches:

• Single-cell technologies:

  • Single-cell RNA sequencing to map CD200/CD200R expression across immune cell populations

  • CITE-seq for simultaneous protein and transcriptome analysis

  • Single-cell spatial transcriptomics to understand tissue-specific expression patterns

• Advanced imaging techniques:

  • Super-resolution microscopy to visualize CD200-CD200R interactions at the immunological synapse

  • Intravital imaging to observe CD200-mediated interactions in living tissues

  • FRET-based reporters to monitor receptor engagement in real-time

• Systems biology approaches:

  • Computational modeling of CD200-CD200R signaling networks

  • Integration of multi-omics data (proteomics, metabolomics, transcriptomics)

  • Machine learning algorithms to identify patterns in CD200-related datasets

• Humanized models:

  • Patient-derived xenografts with preserved CD200 expression

  • Humanized mouse models with human immune components

  • Organoid systems incorporating CD200+ and CD200R+ cells

These approaches will provide deeper insights into contextual factors influencing CD200 function across different tissues and disease states .

How might structural studies of CD200-CD200R interactions inform therapeutic development?

Structural biology approaches offer significant opportunities for therapeutic advancement:

• Key structural determinants for investigation:

  • Precise binding interfaces between CD200 and its receptors

  • Conformational changes upon receptor engagement

  • Structural basis for differential binding to CD200R isoforms

  • Post-translational modifications affecting interaction

• Methodological approaches:

  • X-ray crystallography of CD200-CD200R complexes

  • Cryo-EM studies of larger signaling complexes

  • Hydrogen-deuterium exchange mass spectrometry to map binding interfaces

  • Molecular dynamics simulations to model interaction dynamics

• Therapeutic applications:

  • Structure-based design of small molecule modulators

  • Engineering enhanced-affinity or selective receptor binders

  • Development of antibodies targeting specific epitopes

  • Design of decoy receptors or ligands

• Challenges to address:

  • Glycosylation effects on binding kinetics

  • Membrane environment influences on interaction

  • Multimerization and clustering effects

  • Allosteric regulation mechanisms

Understanding structural constraints determining CD200-CD200R interactions has already proven useful in developing novel small molecule agonists/antagonists, with potential for more precise therapeutic targeting .

What are the most promising translational opportunities for CD200-focused research?

Several translational opportunities stand out for CD200-focused research:

• Diagnostic applications:

  • Improved diagnostic algorithms for B-cell malignancies incorporating CD200

  • Standardized flow cytometry panels for hematological malignancies

  • Prognostic scoring systems based on CD200 expression patterns

• Therapeutic development:

  • Enhanced CAR T-cell designs overcoming CD200-mediated immunosuppression

  • Combination immunotherapy approaches targeting CD200 along with other checkpoints

  • CD200-targeted antibody therapies for CD200-overexpressing malignancies

• Patient stratification:

  • CD200 expression as a biomarker for immunotherapy response

  • Genetic correlates of CD200 expression for precision medicine approaches

  • Liquid biopsy applications to monitor CD200+ circulating tumor cells

• Beyond oncology:

  • CD200-targeting in autoimmune diseases where it plays regulatory roles

  • Applications in transplantation medicine to promote tolerance

  • Neuroinflammatory conditions where CD200's neural expression might be relevant

The most immediate clinical impact will likely come from improved diagnostic accuracy in CLL and other B-cell malignancies, followed by engineered cell therapies that overcome CD200-mediated immunosuppression in multiple myeloma and other CD200+ cancers .